Article
Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures.
Science advances - 1 Dec 2023
Sanz Murillo Marta, Villagran Suarez Amalia, Dederer Verena, Chatterjee Deep, Alegrio Louro Jaime, Knapp Stefan, Mathea Sebastian, Leschziner Andres E
Abstract excerpt
Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial Parkinson's disease (PD) and a risk factor for the sporadic form. Increased kinase activity was shown in patients with both familial and sporadic PD, making LRRK2 kinase inhibitors a major focus of drug development efforts. Although much progress has been made in understanding the structural biology of LRRK2, there are no available...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.